Replies to post #112281 on Biotech Values

[DewDiligence]

ACOR—1Q11 Ampyra sales=$46.8M, down 16% QoQ despite a 7.5% price increase on 3/4/11:

http://finance.yahoo.com/news/Acorda-Therapeutics-Reports-bw-772460741.html?x=0&.v=1

Ampyra sales guidance for 2011 is unchanged at $205-230M, implying average sales of $53-61M per quarter during the next three quarters.